Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection.
JoVE. 2020-06-08; (160):
DOI: 10.3791/59426
Read on PubMed
1. J Vis Exp. 2020 Jun 8;(160). doi: 10.3791/59426.
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity
Detection.
Rengucci C(1), De Maio G(1), Menghi M(2), Benzi F(2), Calistri D(3).
Author information:
(1)Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
IRCCS, Meldola, Italy
(2)Diatech Pharmacogenetics srl.
(3)Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST);
.
Erratum in
J Vis Exp. 2020 Sep 28;(163):.
Nowadays, stool DNA can be isolated and analyzed by several methods. The long
fragments of DNA in stool can be detected by a qPCR assay, which provides a
reliable probability of the presence of pre-neoplastic or neoplastic colorectal
lesions. This method, called fluorescence long DNA (FL-DNA), is a fast,
non-invasive procedure that is an improvement upon the primary prevention system.
This method is based on evaluation of fecal DNA integrity by quantitative
amplification of specific targets of genomic DNA. In particular, the evaluation
of DNA fragments longer than 200 bp allows for detection of patients with
colorectal lesions with very high specificity. However, this system and all
currently available stool DNA tests present some general issues that need to be
addressed (e.g., the frequency at which tests should be carried out and optimal
number of stool samples collected at each timepoint for each individual).
However, the main advantage of FL-DNA is the possibility to use it in association
with a test currently used in the CRC screening program, known as the
immunochemical-based fecal occult blood test (iFOBT). Indeed, both tests can be
performed on the same sample, reducing costs and achieving a better prediction of
the eventual presence of colorectal lesions.
DOI: 10.3791/59426
PMID: 32568232 [Indexed for MEDLINE]